This post is written to the operator, not the injector. It does not tell anyone how to manage a vascular occlusion, and no protocol should be built from a blog post. The clinical content is the medical director’s to write and approve.
What it covers is the part that is an operations problem: everything that decides the outcome is settled weeks before the event, in a document, a stock cupboard and a phone tree. Clinics that do badly here rarely fail at the clinical management. They fail because the agent was expired, or nobody could reach the physician, or the person who noticed was not authorized to act.
Why this one sits differently in your compliance file
A vascular occlusion recognized promptly and reversed completely is a good outcome. It is also, on the federal definition, likely a serious injury. Under 21 CFR § 803.3 that term reaches an event which “necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.”
Intervention to prevent permanent damage is exactly what happened. So the event that your team handled well is the one that belongs in the log, and clinics routinely fail to record it because it ended fine. See adverse event response.
Eight things the written protocol must name
The medical director approves the clinical content. These are the operational elements that have to be in the document either way, each with a name or a number attached rather than a description.
- Recognition criteria, and who has been trained to apply them. Named staff, with training dates. A criterion nobody has been taught is not a control.
- Who is called, and the maximum time to reach them. A named on-call physician, a stated reach time, and a documented fallback when that person does not answer. This is the single most common gap.
- That the reversal agent is stocked, in date, and where it is kept. Hyaluronidase is the agent for hyaluronic acid fillers. The protocol should name the storage location and the person responsible for checking expiry on a stated cycle.
- Who may administer it, under what authority. This is a delegation and standing-order question and it is state-specific. Getting it wrong means the person who recognizes the problem may not be permitted to act on it. See standing orders, protocols and delegation, and check who may inject at all in your state at who can inject, by state.
- The escalation and transfer path. Which facility, how the patient gets there, who calls ahead, and what information travels with them.
- The consent conversation, held before treatment. Occlusion risk discussed and documented at consent, not explained for the first time while it is happening.
- The documentation set. What is recorded, by whom, contemporaneously. Times matter here more than in almost any other note.
- A review date. Protocols go stale as staff, products and premises change.
The four questions that expose an unready clinic
Ask these on a normal Tuesday and the answer arrives immediately or it does not.
- Where is the reversal agent right now, and what is its expiry date?
- Who is on call this afternoon, and what happens if they do not pick up?
- Which staff members on shift today have been trained on recognition, and when?
- Who is authorized to act before the physician arrives?
A clinic that cannot answer all four has a protocol on paper and not in operation. That distinction is what a board is assessing after an event, and it is the same exposure described in your personal license is the collateral.
What this means for you
Treat readiness as a stock and staffing problem rather than a document problem, because the document is easy and the readiness is what fails. Put expiry checking on a named person and a stated cycle, audit it, and keep the record. Establish in writing who may act before a physician is physically present, since that answer is state-specific and it decides whether recognition can be converted into action. Log every occlusion, including the ones reversed completely, both because the federal definition reaches them and because a contemporaneous note is the only durable evidence that the management was appropriate. And run the four questions above unannounced, because the gap between the binder and the building is where this goes wrong. Our standards are at clinical standards.
Related reading
Frequently asked questions
Does a med spa have to stock hyaluronidase?
Requirements vary by state and by what the medical director’s protocol specifies, so check both. As a practical matter, a clinic injecting hyaluronic acid fillers without immediate access to the reversal agent has an operational gap that is difficult to defend after an event.
Who can administer the reversal agent?
That depends on state scope-of-practice rules and on the delegation or standing order your medical director has put in place. Settle it in writing in advance, because the person who recognizes an occlusion may not be the person permitted to act on it.
Is a vascular occlusion reportable if the patient recovers fully?
Documentation and reporting are separate questions, but note that the federal definition of serious injury in 21 CFR § 803.3 reaches an event necessitating intervention to preclude permanent impairment or damage. That can be met even where the outcome is complete recovery, so log it.
What is the most common failure in these protocols?
Not having a named on-call physician with a maximum reach time and a documented fallback. Clinics commonly name a person and never test whether that person is reachable during operating hours.
Should occlusion risk be in the consent?
Yes, discussed and documented before treatment. A risk explained for the first time while it is materializing is a consent problem on top of a clinical one.
This is general information, not legal advice, and it is not clinical guidance. Rules vary by state and change. Confirm your own facts with counsel.